Immutep to Present at Investor Conferences
SYDNEY, AUSTRALIA, May 20, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune diseases, announces Immutep has been invited to present at investor conferences, as outlined below.
Wilsons Rapid Insights – 26 May 2022
Jefferies Australia MedTech/Biotech Summit – 26 & 27 May 2022
Information: Please contact your Jefferies representative to register. For questions, please email [email protected]
Jefferies Global Healthcare Conference – 8 to 10 June 2022
Immutep’s current lead product candidate is eftilagimod alpha (“efti” or “IMP321”), a soluble LAG-3 fusion protein (LAG-3Ig), which is a first-in-class antigen presenting cell (APC) activator being explored in cancer and infectious disease. Immutep is also developing an agonist of LAG-3 (IMP761) for autoimmune disease. Additional LAG-3 products, including antibodies for immune response modulation, are being developed by Immutep’s large pharmaceutical partners.
Further information can be found on the Company’s website www.immutep.com or by contacting: